Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OWC Pharmaceuticals Research Corporation (EM) OWCP

OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in December 2014. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel.


EXPM:OWCP - Post by User

Comment by B8lair8on Feb 11, 2019 1:07am
369 Views
Post# 29345225

RE:RE:RE:Massive volume today ...

RE:RE:RE:Massive volume today ...Find this over on Investors hub. Up to a 500 to 1 reverse split, that would be it.
B.

FOR the authorization of our Board of Directors to effect one reverse stock split of our outstanding Common Stock, $0.00001 par value per share, at any ratio up to 1-for-500, at such time as our Board of Directors shall determine, in its sole discretion, during the Company’s 2019 fiscal year ending December 31, 2019
<< Previous
Bullboard Posts
Next >>